Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Entera Bio Ltd.NASDAQ: ENTX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 44.9% from a year ago
Total equity stood at $10.69M at the end of Q1 FY2026, down 44.9% from a year earlier and down 18.4% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Total equity amounted to 81.4% of total assets at the end of Q1 FY2026, down 8.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -44.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 13.1M USD
- Year-over-year change
- +62.1%
- 4-year CAGR
- -12.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.1M | +62.1% |
| FY2024 | 2024-12-31 | 8.08M | -22.2% |
| FY2023 | 2023-12-31 | 10.39M | -11.6% |
| FY2022 | 2022-12-31 | 11.75M | -47.9% |
| FY2021 | 2021-12-31 | 22.57M | — |
Total Equity vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total equity of $10.69M is the 7th highest of the 10 companies compared; the peer median is $23.19M.
- Its year-over-year change of -44.9% is the 7th highest of 10, against a peer median of -22.4%.
- Total equity amounts to 81.4% of total assets for ENTX, versus a peer median of 78.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $241.48M | -22.4% | -16.6% | 88.7% | |
| Mar 2026 | $87.48M | -43.8% | -28.0% | 65.5% | |
| Mar 2026 | $52.93M | +56.5% | -8.1% | 89.7% | |
| Mar 2026 | $26.5M | -47.5% | +60.1% | 22.5% | |
| Mar 2026 | $23.19M | +135.3% | +19.4% | 78.1% | |
| Apr 2026 | $13.22M | -11.3% | -20.9% | 89.0% | |
| Mar 2026 | $10.69M | -44.9% | +3.7% | 81.4% | |
| Mar 2026 | $6.07M | -88.2% | -52.3% | 12.2% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$45.84M | -1003.5% | -30.8% | 68.6% |
| Mar 2026 | -$227.98M | +29.3% | — | 122.3% | |
| Peer median (excluding ENTX) | $23.19M | -22.4% | -18.8% | 78.1% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.